Gatekeeping role of Nf2/Merlin in vascular tip EC induction through suppression of VEGFR2 internalization

Jung Hyun Bae1,2, Myung Jin Yang1,2, Seung-hwan Jeong2, JungMo Kim2, Seon Pyo Hong2, Jin Woo Kim3, Yoo Hyung Kim2†, Gou Young Koh1,2*

In sprouting angiogenesis, the precise mechanisms underlying how intracellular vascular endothelial growth factor receptor 2 (VEGFR2) signaling is higher in one endothelial cell (EC) compared with its neighbor and acquires the tip EC phenotype under a similar external cue are elusive. Here, we show that Merlin, encoded by the neurofibromatosis type 2 (NF2) gene, suppresses VEGFR2 internalization depending on VE-cadherin density and inhibits tip EC induction. Accordingly, endothelial NF2 depletion promotes tip EC induction with excessive filopodia by enhancing VEGFR2 internalization in both the growing and matured vessels. Mechanistically, Merlin binds to the VEGFR2–VE-cadherin complex at cell-cell junctions and reduces VEGFR2 internalization–induced downstream signaling during tip EC induction. As a consequence, nonfunctional excessive sprouting occurs during tumor angiogenesis in EC-specific Nf2-deleted mice, leading to delayed tumor growth. Together, NF2/Merlin is a crucial molecular gatekeeper for tip EC induction, capillary integrity, and proper tumor angiogenesis by suppressing VEGFR2 internalization.

INTRODUCTION

The key biological process in sprouting angiogenesis is to balance the formation of tip and stalk endothelial cells (ECs), i.e., tip-stalk specification (1–3). These two specified EC subtypes are morphologically and functionally distinct, but their formations are closely related. Tip ECs are highly motile with many long and dynamic filopodia and induced by vascular endothelial growth factor A (VEGF-A) (given as VEGF hereafter) signaling (4, 5), whereas stalk ECs are highly proliferative with fewer filopodia and regulated mainly by Notch signaling (1, 2). These functionally distinct tip and stalk cells coordinate into a branched network of vessels for sprouting angiogenesis (1–5). The ECs induced as tip ECs more frequently have a higher delta-like ligand 4 (Dll4) level, which activates Notch signaling in neighboring ECs. High Notch signaling activity inhibits tip EC behaviors while promoting the stalk cell phenotype (6, 7). Molecularly, ligand-induced, clathrin-dependent VEGF receptor 2 (VEGFR2) internalization is the initial process for intracellular activation of VEGFR2 signaling (8–12), while, morphologically, tip EC induction is a foremost step for sprouting angiogenesis (13, 14). However, a persistent puzzle is how one particular EC has higher VEGFR2 signaling activity than its neighbors and is thus fated to become a tip EC during sprouting angiogenesis.

We and others have recently reported that the final effectors of the Hippo pathway, Yes-associated protein (YAP) and its paralog transcriptional coactivator with PDZ-binding motif (TAZ) are essential in the morphogenesis of tip ECs and proliferation of stalk cells (15–17). In this biological process, large tumor suppressors 1 and 2 (LATS1/2) act as the direct upstream regulators of YAP/TAZ in the canonical Hippo pathway (15–17). Although mammalian sterile 20–like kinase 1 (MST1) acts as an upstream regulator of LATS1/2, we found that MST1 rather promotes nuclear import of FOXO1 (forkhead box O1) in response to hypoxia, leading to endothelial polarity at the tip ECs during sprouting angiogenesis (18).

Merlin, encoded by the neurofibromatosis type 2 gene NF2 (referred here as Nf2 for the gene and Merlin for the protein) is ubiquitously expressed in all types of cells and acts as an upstream regulator of the Hippo pathway (19, 20). Merlin inactivates the transcriptional activities of YAP/TAZ (19, 21) by direct phosphorylation of LATS1/2, which leads to a block of their proteasomal degradations. Beyond Merlin’s function in the Hippo pathway (19), as a membrane-associated protein, it plays a gatekeeping role in signal transduction from membrane receptors in a cell density–dependent manner (21–23). Under low cell density, Merlin is phosphorylated at serine-518 [pMerlin(S518)], which renders the protein inactive (19, 21). Inactive Merlin remains in the cytoplasm and allows transduction of membrane receptor signals into cells (23, 24). In contrast, at a high cell density, Merlin is dephosphorylated, leading to its activation, which inhibits propagation of the membrane receptor signals (23, 25). Active Merlin binds to cadherin-containing complexes and directly suppresses internalization of membrane receptors, such as epidermal growth factor receptor and Notch (26, 27).

Nevertheless, it has not been investigated whether endothelial Merlin is essential in sprouting angiogenesis and, in detail, which intracellular signaling is regulated by endothelial Merlin.

Here, we unveil that endothelial Merlin is dispensable for tip EC induction by activating intracellular VEGFR2 downstream signaling during sprouting angiogenesis. It forms a complex with VEGFR2 and VE-cadherin and acts as a gatekeeper for VEGFR2 internalization. This entire process seems not to be dependent on the Hippo pathway. Considering different density of VE-cadherin in each EC at angiogenic front (28), Merlin in ECs with relatively low VE-cadherin density compared with neighboring ECs allows high VEGF/VEGFR2

1Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea. 2Center for Vascular Research, Institute for Basic Science (IBS), Daejeon 34141, Republic of Korea. 3Department of Biological Sciences, KAIST, Daejeon 34141, Republic of Korea. *Corresponding author. Email: gykoh@kaist.ac.kr (G.Y.K.); yoohyungk@gmail.com (Y.H.K.) †Present address: Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea.
with siCont-ECs, 1.97-fold increase of DLL4 but 32.3 and 54.7% reductions of HES1 and HEY1 were observed in siNf2-ECs (fig. S3E), implying that Merlin regulates DLL4-Notch signaling by presumably suppressing VEGFR2 signaling. Furthermore, an increased number (2.0-fold) of sprouts were also found in ex vivo cultured aortic rings derived from Nf2ΔEC mice compared with those derived from WT mice (fig. S3, F to I). These data indicate that endothelial Merlin is a negative regulator of tip EC induction in sprouting angiogenesis.

**RESULTS**

**Endothelial Merlin is a negative regulator in sprouting angiogenesis**

To examine the presence of Nf2 in ECs, we analyzed publicly available data (GSE27238, GSE19284, and GSE86788), which indicated that Nf2 mRNA expression in retinal ECs was almost equivalent to that of retinal non-ECs in mice at postnatal day 8 (P8) and was similarly expressed in both tip and stalk retinal ECs at P2 (fig. S1, A and B). Moreover, its level was not changed from P6 to P50, while mRNA expressions of tip EC markers such as EC-specific molecule 1 (Ecm1), angiopoietin 2 (Angpt2), and placental growth factor (Plgf) were gradually reduced in the retinal ECs along with postnatal development in mice (fig. S1C). Thus, Nf2 is equivalently expressed in ECs regardless of developmental stages, as well as in non-ECs.

To investigate the role of endothelial Merlin in sprouting angiogenesis, we generated Nf2ΔEC mice by crossing Nf2floxflox mice (29) with VE-cadherin Cre-ER T2 mice (30). With this mutant, we confirmed EC-specific deletion of Merlin by 91.5% but no detectable changes of VE-cadherin and VEGFR2 in lung ECs at 4 days after tamoxifen administration (fig. S1, D to F). Cre-ER T2- positive but flox/flox-negative mice among the littermates were used as wild-type (WT) mice. EC-specific deletion of Nf2 in Nf2ΔEC mice from P2 led to impaired retinal angiogenesis at P6 (fig. 1A). Compared with WT mice, Nf2ΔEC mice exhibited reduced radial length (33.0%) and proliferative 5-ethyl-2′-deoxyuridine-positive (EdU+) ECs (83.7%) but showed increased vascular branching (3.9-fold), numbers of sprouts (3.2-fold) and filopodia (2.6-fold), vascular density (1.8-fold), and severe vascular leakage at the vascular aneuphoric front, whereas filopodial length was comparable between the two animal groups (fig. 1, B to H). Notably, protein level of ESM1, a marker for tip cell state (31), was increased (10.1-fold) in the vascular front in Nf2ΔEC mice compared with WT mice at P6 (fig. 1, E and F). Moreover, EC-specific deletion of Nf2 in Nf2ΔEC mice from P3 led to severely impaired formation of retinal deep vascular plexus, whereas there were 9.9 and 19.9% reductions of radial length and vascular density of retinal superficial vascular plexus at P12 (fig. S2, A to C). To compare EC migration in the presence and depletion of Merlin, we transfected small interfering RNA (siRNA) for control (siCont) or the Nf2 gene (siNf2) into primary cultured human umbilical vein ECs (HUVECs), confirmed knockdown efficiency of the Nf2 gene in siNf2-ECs (HUVECs transfected with siNf2) by immunoblotting for Merlin (85.3% reduction) (fig. S2, D and E), and used the Cell-Insert 2 Well for wounding and migration assay (fig. S2F). Compared with siCont-ECs, siNf2-ECs showed 52.1% less directional migration toward the wounding area (fig. S2, G and H), which is consistent to the findings of the growing retinal vessels in vivo.

To explore whether Merlin regulates DLL4-Notch signaling, we compared protein level of DLL4 in the retinal vascular front of WT and Nf2ΔEC mice at P6 and found that the retinal ECs in Nf2ΔEC mice had 8.1-fold higher DLL4 compared with those in WT mice (fig. S3, A to C). We also compared mRNA levels of DLL4, HES1, and HEY1 between the primary cultured HUVECs transfected with siCont (siCont-ECs) and siNf2 (siNf2-ECs) (fig. S3D). Compared

**Endothelial Merlin negatively regulates tip EC induction by suppressing VEGF/VEGFR2 signaling**

Given that VEGF/VEGFR2 signaling is central in sprouting angiogenesis (1, 2), we questioned whether Nf2 deletion in ECs would alter VEGF/VEGFR2 signaling. Gene set enrichment analysis (GSEA) on freshly isolated brain ECs at P9 revealed that in Nf2ΔEC compared with WT mice, VEGF target genes and VEGF/VEGFR2 signaling pathway genes were up-regulated [ABE_VEGFA targets, NES (normalized enriched score) = 1.47, P < 0.01; WP_VEGFA/VEGFR2 signaling pathway, NES = 1.8, P < 0.01; fig. S4B]. Furthermore, in Nf2ΔEC mice compared with WT mice, we found up-regulation of Rspo3, Robo1, Slit2, Esm1, and Bmp4, all genes related to promoting sprouting angiogenesis (fig. S4A).

Accordingly, systemic treatment with DC101 (a VEGFR2-blocking antibody) at P4 and P5 abolished excessive tip EC induction in Nf2ΔEC mice (fig. 2, A to C). The treatment reduced branching points by 71.2% and numbers of filopodia by 71.6% in the retinal vessels compared with control immunoglobulin G (IgG) antibody treatment, whereas these values were 46.8 and 53.4%, respectively, in WT mice (fig. 2, B and C). To further address the role of endothelial Nf2 in the response to VEGF stimulation, we compared filopodia formation in siCont-ECs and siNf2-EC after the scratch wounding and VEGF stimulation (fig. 2D). siCont-ECs and siNf2-ECs showed comparable numbers of phalloidin+ filopodia at the scratch border of the cell membrane. However, VEGF treatment (50 ng/ml) for 6 hours increased the number of phalloidin+ filopodia by 1.9-fold at the leading edge of siCont-ECs (fig. 2, E and F), notably, by 3.9-fold in siNf2-ECs (fig. 2, E and F). Moreover, to address the selectivity of Merlin’s gatekeeping role in VEGFR2 signaling, we simulated the aortic rings of WT and Nf2ΔEC mice with Angpt2, basic fibroblast growth factor (bFGF), lysophosphatidic acid (LPA), or VEGF (fig. S5, A and B). Although Angpt2, bFGF, and LPA increased the number of vascular sprouts at different magnitudes in both aortas, no enhancements of vascular sprouting formation were found in the aortas of Nf2ΔEC mice compared with those of WT mice (fig. S5, B and C). In comparison, VEGF enhanced vascular sprout formation by 1.7-fold (fig. S5, B and C), implying that endothelial Merlin negatively regulates tip EC induction by selectively suppressing VEGF/VEGFR2 signaling.

**Merlin-mediated suppression of tip EC induction is not crucially associated with YAP/TAZ activity**

To interrogate whether YAP/TAZ mediates the Merlin-induced suppression of tip EC induction, we generated Yap/TAZΔAC and Nf2/Yap/TazΔAC mice by crossing double YapΔAC-TazΔAC mice (32, 33) and triple Np63fl/fl-YapΔAC-TazΔAC mice with VE-cadherin-CreER T2 mice (fig. 3A) and compared vascular phenotypes of growing retinal vessels among them. We used TAZ protein intensity in the retinal vessels as a surrogate marker of YAP/TAZ activity (fig. S6, A and B). TAZ was mainly expressed at the vascular front in WT mice. Nf2ΔAC
mice showed elevated TAZ protein intensity (7.8-fold) in both the front and the plexus compared with WT mice, which exhibited no difference in TAZ intensity between the vascular front and plexus. However, both Yap/Taz\textsuperscript{ΔEC} and Nf2/Yap/Taz\textsuperscript{ΔEC} mice showed 88.1 and 94.9% reduced TAZ levels, respectively (fig. S6, A and B). In keeping with what we and others have previously reported (15–17), Yap/Taz\textsuperscript{ΔEC} mice had blunt-ended, aneurysm-like structures with few sprouts (95.9% reduction) and limited filopodia formation.
(80% reduction) compared with those of WT mice, whereas Nf2\textsuperscript{iΔEC} mice exhibited excessive filopodia and hyperplastic vascular growth at the vascular front, as described above (Fig. 3, A to C). Nevertheless, numbers of sprouts and filopodia of Nf2/Yap/Taz\textsuperscript{iΔEC} mice were higher (2.1- and 1.5-fold) than in WT mice and still similar to those of Nf2\textsuperscript{iΔEC} mice (Fig. 3, A to C), implying that the Merlin-induced suppression of tip EC induction seems to be not crucially related to the Hippo pathway.

We obtained comparable findings with an ex vivo sprouting assay using the aortic ring derived from the mice (Fig. 3D). Although the aortic ring of Yap/Taz\textsuperscript{iΔEC} mice formed fewer and shorter sprouts, by 82.3 and 63.9%, respectively, compared with WT mice, the aortic rings of Nf2/Yap/Taz\textsuperscript{iΔEC} mice formed increased sprout number (1.22-fold) and lengths (1.31-fold) compared with WT animals (Fig. 3, E to F). In addition, both Nf2\textsuperscript{iΔEC} and Nf2/Yap/Taz\textsuperscript{iΔEC} mice exhibited comparable number and length of sprouts. Thus, the

![Image](https://example.com/image.png)
Merlin-induced suppression of tip EC induction again appeared to be unrelated to the Hippo pathways.

**Endothelial Merlin negatively governs tip EC induction by reducing VEGFR2 internalization during sprouting angiogenesis**

Our GSEA showed up-regulation of genes related to receptor internalization and endocytosis (GO_Receptor internalization, NES = 1.67, P < 0.01; KEGG_Endocytosis, NES = 1.366, P < 0.01) in Nf2ΔEC mice compared with WT mice (fig. S4C). For this reason, we examined spatial regulation of the VEGFR2 trafficking process in growing retinal vessels of WT and Nf2ΔEC mice. To visualize distribution of VEGFR2 internalization, we administered Alexa fluorescent dye–labeled VEGF (Fluor-VEGF) intravitreally into the retina at P6 (Fig. 4A). The Fluor-VEGF spots were predominantly localized to the vascular front of retinal vessels at 1 hour and abruptly disappeared at 2 hours after injection in WT mice. In contrast, Nf2ΔEC mice compared with WT mice had Fluor-VEGF spots 3.7-fold more localized to the vascular front at 1 hour and reduced at a similar rate but still persistent and 9.8-fold higher at 3 hours after the injection (Fig. 4, B and C, and fig. S7, A and B). We confirmed the VEGF internalization into the endosome by detection of the colocalization of Fluor-VEGF and early endosomal marker EEA1 (fig. S7, C and D).

Because the major intracellular signaling role of VEGFR2 is activation of extracellular signal–regulated protein kinases 1 and 2 (ERK1/2) and Akt (8, 9), we measured phosphorylated ERK1/2 (pERK1/2) at Thr 202/Tyr 204 and phosphorylated Akt at Ser 473 in the ECs of growing retinal vessels. pERK1/2 at Thr 202/Tyr 204 and phosphorylated Akt at Ser 473 was 5.0- and 4.2-fold enhanced in the vascular front of retinal vessels in Nf2ΔEC mice compared with WT mice (Fig. 4, D and E, and fig. S7, E and F). Moreover, to delineate whether the VEGFR2 internalization is clathrin dependent, we performed intravitreal injection of dimethyl sulfoxide (DMSO) (5.0% in 0.5 μl) as a control vehicle or Dynasore (200 μM in 0.5 μl), a cell-permeable inhibitor of clathrin-dependent internalization (8, 34), in the neonatal mice.

DMSO did not affect the enhancements of ERK1/2 phosphorylation and numbers of branching points and filopodia in Nf2ΔEC mice versus WT mice (Fig. 4, D and E). However, Dynasore largely
lessened the enhancements of ERK1/2 phosphorylation and numbers of branching points and filopodia by 81.4, 75.1, and 76.4% in Nf2<sup>i∆EC</sup> mice versus WT mice, respectively (Fig. 4, D and E). To exclude the off-target effect of Dynasore (34), we performed the same experiment with intravitreal injection of Pitstop-2 (200 μM in 0.5 μl), a selective and cell membrane-permeable inhibitor of clathrin-mediated endocytosis by competitively inhibiting clathrin terminal domain (35), and obtained comparable results (fig. S8, A to C). Thus, endothelial Merlin negatively regulates tip EC induction by suppressing VEGFR2-ERK1/2 and Akt signaling mainly through inhibiting ligand-induced, clathrin-dependent VEGFR2 internalization.

Fig. 4. Endothelial Merlin suppresses tip EC induction by repressing VEGFR2 internalization during sprouting angiogenesis. (A to C) Diagram depicting experiment for intravitreal injection and follow up of Alexa Fluor 488 dye–labeled VEGF-A (Fluor-VEGF; 0.5 μg in 0.5 μl) in WT and Nf2<sup>i∆EC</sup> neonatal mice. Representative images and comparisons of Fluor-VEGF at the vascular front of retinal vessels in WT and Nf2<sup>i∆EC</sup> mice. Scale bars, 10 μm. Fluor-VEGF spot is presented as percentage per CD31<sup>+</sup> area. n = 4 mice per group from two independent experiments. Dots and bars indicate means ± SD. P values by Welch’s one-way ANOVA test followed by Dunnett’s T3 test. (D and E) Images and comparisons of phosphorylated ERK1/2 (pERK1/2) and indicated parameters in the vascular front of CD31<sup>+</sup> retinal vessels at 24 hours after intravitreal injection of Dynasore (200 μM in 0.5 μl) into WT and Nf2<sup>i∆EC</sup> mice at P5. Red asterisks indicate tip ECs. Scale bars, 100 μm (top and middle) and 50 μm (bottom). pERK1/2 intensity is normalized by those of WT treated with dimethyl sulfoxide (DMSO; 5%, 0.5 μl). Each dot indicates a value from one mouse and n = 5 mice per group from three independent experiments. Vertical bars indicate means ± SD. P values by Welch’s one-way ANOVA test followed by Dunnett’s T3 test.
Endothelial Merlin suppresses VEGFR2 internalization under high cell density through physical interaction with VEGFR2 and VE-cadherin

We examined the localization and density of Merlin in HUVECs under sparse (low cell density, low VE-cadherin density) or dense (high cell density, high VE-cadherin density) culture conditions. Immunofluorescence (IF) staining analysis revealed that Merlin was highly distributed at the cell membrane when ECs were in contact with adjacent ECs under dense culture conditions. In contrast, under sparse culture conditions, Merlin was scarcely distributed at the cell membrane when ECs were not in contact with each other (Fig. 5, A and B). Moreover, Merlin was colocalized with VE-cadherin at the cell membrane (Fig. 5C). Immunoprecipitation with VEGFR2 antibody also indicated that Merlin formed a complex with VEGFR2 and VE-cadherin in HUVECs under dense but less under sparse culture conditions (Fig. 5, D and E). Moreover, the amount of Merlin binding to VEGFR2 was increased as the EC density was increased (Fig. S9, A and B). Notably, immunoprecipitation analysis with streptavidin-binding peptide (SBP)-tagged Merlin revealed that Merlin was physically bound to VEGFR2 but not to other representative angiogenic membrane receptor tyrosine kinases (VEGFR3 and Tie2) (Fig. 5, F and G). To delineate whether VE-cadherin (CDH5) is required for the Merlin-VEGFR2 complex formation, we depleted VE-cadherin by transfection of siCDH5 into densely cultured HUVECs (siCDH5-ECs). Immunoprecipitation with VEGFR2 antibody did not pull down a notable amount of Merlin in siCDH5-ECs but pulled down a substantial amount of Merlin in siCont-ECs (Fig. 5, H and I), indicating that VE-cadherin is required for formation of VEGFR2-Merlin complex. Together, these results imply that Merlin exclusively binds to VEGFR2 among the angiogenic receptor tyrosine kinases that form the VE-cadherin–Merlin–VEGFR2 complex at high cell density in HUVECs.

pMerlin(S518) was common in sparsely cultured HUVECs but scarcely detected in densely cultured HUVECs (Fig. 5, J and K). Furthermore, immunoblotting analysis revealed a barely detectable pMerlin(S518) in siCDH5-ECs but detectable in densely cultured siCont-ECs (Fig. S9C). To further analyze whether S518 of Merlin is a critical determinant in VEGFR2 internalization, densely cultured siNF2-ECs were transfected with retrovirus encoding empty gene (Control), Flag-NF2-WT (NF2-WT), Flag-NF2-S518A (S518A), or Flag-NF2-S518D (S518D), stimulated with VEGF for 15 min and examined VEGFR2 internalization into the early endosomal compartment by covisualization of VEGFR2 and Rab5 (Fig. S11C). Compared with Control, NF2-WT and S518A showed 76.1 and 69.3% reductions of VEGFR2 internalization, but S518D showed no difference of VEGFR2 internalization (Fig. S11, C and D). Moreover, compared with Control, NF2-WT and S518A showed 62.7 and 68.3% reductions in the VEGF-induced phosphorylation of VEGFR2, VEGFR2 (Y1175), and ERK1/2 (Thr202/Tyr204), but S518D showed no differences of the phosphorylations (Fig. 6, E and F). These findings clarify that Merlin phosphorylation on S518 critically contributes to VEGFR2 internalization and downstream signaling depending on cell density, potentially leading to reduced tip EC induction during sprouting angiogenesis.

Endothelial deletion of Merlin induces excessive VEGF-induced filopodial formation at mature stable vessels

ECs of the vascular plexus have a high density of VE-cadherin and are exposed to low VEGF compared with ECs in the vascular front during sprouting angiogenesis. We further elucidated whether endothelial Merlin still restrains VEGF-induced filopodial protrusion in the vascular plexus at the single EC level, we first generated WT^{△EC-TR} and Nf2^{△EC-TR} mice by crossing Nf2^{△EC} mice with Rosa26-tdTomato reporter mice. We then administered a low dose (0.5 µg) of tamoxifen at P2 for the mosaic induction of tdTomato in the retinal vessels of WT^{△EC-TR} and Nf2^{△EC-TR} mice (Fig. 7A). Both WT^{△EC-TR} and Nf2^{△EC-TR} mice exhibited few but a similar number of filopodia in tdTomato+ ECs at the vascular plexus at 6 hours after intravitreal injection of Fluo-VEGF in WT mice (Fig. S12, A to D). However, compared with WT mice, VEGF internalization was 7.7-fold increased at 1 hour and rapidly reduced at 2 hours after Fluor-VEGF injection in Nf2^{△EC} animals (Fig. S12, A to D).

To visualize filopodial protrusion in the vascular plexus at the single EC level, we first generated WT^{△EC-TR} and Nf2^{△EC-TR} mice by crossing Nf2^{△EC} mice with Rosa26-tdTomato reporter mice. We then administered a low dose (0.5 µg) of tamoxifen at P2 for the mosaic induction of tdTomato in the retinal vessels of WT^{△EC-TR} and Nf2^{△EC-TR} mice (Fig. 7A). Both WT^{△EC-TR} and Nf2^{△EC-TR} mice exhibited few but a similar number of filopodia in tdTomato+ ECs at the vascular plexus at 6 hours after intravitreal phosphate-buffered saline (PBS) treatment (Fig. 7, B and C). However, at 6 hours after intravitreal VEGF injection, the number of filopodial protrusions increased 3.1-fold in Nf2^{△EC-TR} mice compared with WT^{△EC-TR} mice (Fig. 7, B and C).
Fig. 5. Dephosphorylated Merlin forms a complex formation with VEGFR2 and VE-cadherin at high cell density. (A and B) Representative images and comparisons of cell membrane localization of Merlin in sparsely and densely cultured HUVECs. Scale bars, 50 µm. Merlin intensity at cell membrane in sparse HUVECs regards as 1. n = 3 per group from two independent experiments. Vertical bars indicate means ± SD. *P* values by two-tailed *t* test. (C) Images of subcellular localization of Merlin in cell-cell contact (white arrowheads) and no cell contact area (white arrows) in cultured HUVECs. Similar finding was observed in three independent experiments. Scale bar, 50 µm. (D to G) Immunoblotting and comparison of indicated proteins after immunoprecipitation with SBP-tag, IgG, or anti-VEGFR2 antibody in sparsely (S) and densely (D) cultured HUVECs. n = 3 per group from three independent experiments. Vertical bars indicate means ± SD. *P* values by Welch’s one-way ANOVA test followed by Dunnett’s T3 test. (H and I) Immunoblotting and comparison of indicated proteins after immunoprecipitation with IgG or anti-VEGFR2 in densely cultured siCont-ECs and siCDH5-ECs. n = 3 per group from three independent experiments. Vertical bars indicate means ± SD. *P* values by two-tailed *t* test. (J and K) Immunoblotting and comparison of phosphorylated Merlin(S518) and Merlin in sparsely and densely cultured HUVECs. n = 3 per group from three independent experiments. Vertical bars indicate means ± SD. *P* values by two-tailed *t* test. (L and M) Immunoblotting and quantification of indicated Flag-tagged proteins after immunoprecipitation with anti-VEGFR2 antibody in densely cultured HUVECs transfected with retrovirus encoding empty (Control), Flag-tagged NF2 (NF2-WT), nonphosphorylatable NF2 (S518A), or phosphomimetic NF2 (S518D). n = 3 per group from three independent experiments. Vertical bars indicate means ± SD. *P* values by Welch’s one-way ANOVA test followed by Dunnett’s T3 test. (N) Diagram depicting a proposed model of VEGFR2/Merlin/VE-cadherin interaction.
ECs of VEGF-enriched organs such as the thyroid gland and small intestinal villi (37, 38). In the adult thyroid gland of NF2<sup>ΔEC</sup> mice, vascular density, filopodial number, and extravascular dextran leakage were 1.2-, 3.3-, and 4.8-fold higher than in WT mice (Fig. 7, D to F, and fig. S13, F and G). Moreover, in the adult small intestinal villi of NF2<sup>ΔEC</sup> mice, filopodial protrusions in the capillary plexus of the jejunum and ileum were respectively 1.8- and 2.8-fold higher than in WT mice (Fig. 7, G and H). In contrast, no apparent differences
in the vascular density, filopodial number, and extravascular dextran leakage in adult retinas were found between WT and Nf2i∆EC mice (fig. S13, A to E). Thus, endothelial Merlin acts as a negative rheostat to maintain vascular stability and integrity.

**Endothelial Merlin is required to constitute proper tumor angiogenesis**

To explore the roles of endothelial Merlin in tumor vessels, we used the subcutaneous Lewis lung carcinoma (LLC) tumor–implanted
model (39) in WT and Nf2<sup>i∆EC</sup> mice. After 3 weeks of implantation, tumors of Nf2<sup>i∆EC</sup> mice were pale and smaller (78.5% less in volume) compared with those of WT mice (Fig. 8, A to C). Notably, compared with tumors of WT mice, those of Nf2<sup>i∆EC</sup> mice had an uneven distribution of CD31<sup>+</sup> blood vessels with more necrotic areas but had higher (2.2- and 4.3-fold) vascular densities in peri- and intratumoral regions (Fig. 8, D to K). Moreover, lectin-perfused tumor vessels were 88% decreased, and the GLUT1<sup>+</sup> (glucose transporter 1) hypoxic area

---

**Fig. 8.** Endothelial Nf2 deletion delays tumor growth by generation of nonperfused hypersprouting tumor vasculature. (A to C) Diagram depicting experimental schedule for EC-specific deletion of Nf2 in tumor vessels by tamoxifen administration, implantation LLC cells, and their analyses at day 21 after the implantation. Comparison of LLC tumor growth in WT and Nf2<sup>i∆EC</sup> mice. Gross findings of LLC tumors harvested at day 21. Scale bar, 10 mm. Dots and bars indicate means ± SD. Plot indicates each individual tumor growth and <i>n</i> = 6 mice per group from two independent experiments. *<i>P</i> < 0.05 versus WT by two-tailed <i>t</i> test. (D to I) Representative images and comparisons of GLUT1<sup>+</sup> area, blood vessel densities of peri- and intratumoral regions, and lectin perfusion of tumor vessels in the tumors of WT and Nf2<sup>i∆EC</sup> mice at day 21 after implantation. Scale bars, 5 mm (D) and 100 μm (F and H). Lectin<sup>+</sup> area is presented as a percentage per CD31<sup>+</sup> area. Each dot indicates a value from one mouse and <i>n</i> = 5 to 6 mice per group from two independent experiments. Vertical bars indicate means ± SD. <i>P</i> values by two-tailed <i>t</i> test. (J and K) Hematoxylin and eosin–stained images of tumor sections and comparison of necrotic areas (black dotted line) of tumors harvested on day 21. Necrosis is presented as a percentage per total sectional area. Scale bar, 5 mm. Each dot indicates a value from one mouse and <i>n</i> = 6 mice per group from two independent experiments. Vertical bars indicate means ± SD. <i>P</i> values by two-tailed <i>t</i> test.
was 3.6-fold higher (Fig. 8, D to I). Furthermore, similar phenotypes were observed in $N_{f2}^{\Delta EC}$ mice in which Merlin was deleted in tumor vessels after tumor implantation (fig. S14A). After 3 weeks of implantation, $N_{f2}^{\Delta EC}$ mice showed 80.6% less tumor volume compared with WT mice (fig. S14, B and C). The peritumoral region of $N_{f2}^{\Delta EC}$ mice had a vessel density comparable to that of WT mice, but vessel density in the intratumoral region of $N_{f2}^{\Delta EC}$ mice was 2.8-fold compared with WT animals (fig. S14, D to G). In addition, vascular tumor perfusion of $N_{f2}^{\Delta EC}$ mice was impeded by 30%, but tumors had 2.7- and 2.3-fold more hypoxic area and necrotic area, respectively, compared with WT mice (fig. S14, F to I). Thus, endothelial Merlin is required to constitute proper and patent tumor vessels.

**Specification into endothelial tip and stalk cells is strictly dependent on Merlin in tumor angiogenesis**

To gain further insight into the roles of endothelial Merlin in tumor vessels, we performed single-cell RNA sequencing (scRNA-seq) on the tumor ECs of implanted LLC tumors of WT and $N_{f2}^{\Delta EC}$ mice (Fig. 9A). Through unsupervised clustering, we identified four distinct subpopulations: tip-like, stalk-like, transitional, and proliferative ECs (Fig. 9B and fig. S15) (40, 41). Notably, compared to tumor ECs of WT mice, those of $N_{f2}^{\Delta EC}$ mice exhibited an enriched tip-like EC population but a reduced stalk-like EC population (Fig. 9C). Through Gene Ontology (GO) term analysis with Enrichr (42), we found that VEGFA-VEGFR2 signaling, ERK1/2 cascade, endocytosis regulation, and the VEGFR signaling pathway of WikiPathways and GO biological processes were up-regulated in tumor ECs of $N_{f2}^{\Delta EC}$ mice compared with those of WT mice (Fig. 9D). Consistently, ECs of $N_{f2}^{\Delta EC}$ mice showed up-regulated expression of genes related to tip ECs, hypoxia, endocytosis, and ERK signaling (Fig. 9E). Accordingly, compared with WT mice, $N_{f2}^{\Delta EC}$ mice showed a 9.1-fold higher population of placental growth factor” (PIGF; a representative marker for tip-like ECs) in tumor vessels but 78.3% less atypical chemokine receptor 1” (ACKR1; a representative marker for stalk-like ECs) (Fig. 9, F and G). Thus, our scRNA-seq analysis confirmed that $N_{f2}$ governs specification of tip or stalk cells and that lack of Merlin in tumor ECs up-regulates genes related to VEGFR2 endocytosis, hypoxia, and ERK signaling.

**DISCUSSION**

In this study, we show that Merlin is mainly localized at the cell membrane in vascular ECs, interacts with VEGFR2 and VE-cadherin, and plays a negative role in VEGFR2 intracellular downstream signaling by suppressing VEGFR2 internalization. As a consequence, endothelial Merlin is a gatekeeping regulator for tip EC induction in retinal sprouting angiogenesis during postnatal development, for formations of filopodia and sprouts in matured and established capillary ECs of adults, and for tip cell formation and proper tumor vessel construction in tumor vessels (Fig. 10).

Our analyses of in vivo retinal angiogenesis and the ex vivo aortic ring assay using $N_{f2}^{\Delta EC}$ mice clearly show that endothelial Merlin is a negative regulator of tip EC induction in sprouting angiogenesis. Given that VEGF/VEGFR2 signaling is central in sprouting angiogenesis (1, 2), we questioned whether $N_{f2}$ deletion in ECs alters VEGF/VEGFR2 signaling. The GSEA revealed that $N_{f2}$ suppresses the genes related to VEGF/VEGFR2 signaling and sprouting angiogenesis. In line with this finding, VEGFR2 blockade abolished excessive tip EC induction in $N_{f2}^{\Delta EC}$ mice, whereas VEGFR2 stimulation potentiated filopodia formation at the wounding site of cultured $N_{f2}$-deleted ECs. These results indicate that endothelial Merlin negatively regulates tip EC induction by suppressing VEGF/VEGFR2 signaling. In addition, our findings suggest that Merlin Dll4-Notch regulates signaling by presumably suppressing VEGFR2 signaling for proper tip cell/stalk cell formation in sprouting angiogenesis. Because Dll4-Notch signaling is a critical regulator for tip cell induction (1, 2, 6, 7), a more detailed mechanistic study regarding the roles of Merlin on Dll4-Notch signaling in the tip cell induction is warranted in the future. On the other hand, although Merlin acts as a suppressor of YAP/TAZ transcriptional coactivators through canonical signaling (19, 20), our findings using combined and EC-specific gene deletions in mice indicate that Merlin-mediated suppression of tip EC induction is not critically mediated through the Hippo pathway.

Ligand-induced, clathrin-dependent VEGFR2 internalization is the initial cellular process for downstream activation of VEGFR2 signaling (8–12), which leads to sprouting angiogenesis, including tip EC induction (13, 14). In our in vivo VEGFR2 internalization analysis using growing retinal vessels convincingly demonstrated that endothelial Nf2 deletion prolongs VEGF internalization into the ECs during sprouting angiogenesis. Moreover, major intracellular signaling of VEGFR2, pERK1/2 (Thr202/Tyr204), and pAkt (Ser473) was enhanced, and blockade of clathrin-dependent internalization largely abolished pERK1/2 (Thr202/Tyr204) and reduced the number and length of filopodia in the ECs of growing retinal vessels in $N_{f2}^{\Delta EC}$ mice. On the basis of these findings, we conclude that endothelial Merlin negatively regulates tip EC induction by suppressing VEGFR2-ERK1/2 and Akt signaling mainly through inhibiting ligand-induced, clathrin-dependent VEGFR2 internalization.

We found that Merlin is highly localized at the cell membrane when ECs are in contact with adjacent ECs under dense culture conditions but scarcely localized at the cell membrane when ECs are in contact with adjacent ECs under sparse culture conditions. Notably, Merlin engages in a physical interaction with VEGFR2 and VE-cadherin in dense culture, and it plays a role in VEGFR2 internalization (43, 44). Considering different densities of VE-cadherin in each EC at the angiogenic front (28), inactivated Merlin in ECs with relatively low VE-cadherin density contributes to tip EC induction through relatively high VEGF signals compared with neighboring ECs with high VE-cadherin density (Fig. 9). However, given that endothelial tip and stalk cells, either in physiological or pathological contexts, are in close contact with neighboring cells in vivo, both gatekeeping role of Merlin in VEGFR2 signaling and the adherens junctions may critically contribute to VE-cadherin dynamics and stability for proper spouting angiogenesis and maintaining EC integrity.

Our data reveal that VEGFR2 internalization is differentially regulated in sparse and dense culture conditions. Sparsely cultured HUVECs had an about twofold higher VEGFR2 internalization than densely cultured ECs. In contrast, Merlin-depleted ECs showed increased VEGFR2 internalization, whereas Merlin-overexpressed ECs showed reduced VEGFR2 internalization under dense culture conditions. In line, Lampugnani et al. (44) reported that VE-cadherin restricts VEGFR2 internalization and intracellular signaling by making complex with β-catenin and DEP-1 (density-enhanced phosphatase-1).
at EC-EC contact in dense culture conditions, while this restriction is released in sparse culture conditions. These findings indicate that Merlin, together with membrane-associated β-catenin and phosphatase DEP-1, is a critical, negative rheostat in VEGFR2 internalization and that its main downstream signaling activation depends on cell density, which leads to proper formation of tip ECs during sprouting angiogenesis.

We also questioned whether endothelial Merlin acts as a negative rheostat in matured vessels of VEGF-enriched organs, including thyroid gland and intestinal villi (37, 38). Nf2i-EC mice
An attractive target for disrupting tumor vasculature and delaying tumor growth.

**MATERIALS AND METHODS**

**Mice and treatment**

Specific pathogen-free (SPF) C57BL/6j and R26-tdTomato mice were purchased from the Jackson Laboratory. VE-cadherin-CreER<sup>T2</sup> (30), NF2<sup>B/H</sup> (29), Yap<sup>B/H</sup> (33), and Taz<sup>B/H</sup> (32) mice were transferred, established, and bred in our SPF animal facilities at Korea Advanced Institute of Science and Technology (KAIST) and fed with free access to a standard diet (PMI LabDiet) and water. To induce Cre activity in the CreER<sup>T2</sup> mice, tamoxifen (Sigma-Aldrich, TS648) was given with the following dosages and schedules: For neonatal mice, 100 μg of tamoxifen dissolved in corn oil (Sigma-Aldrich, C8267) was injected into the stomach daily from P2 to P4 or P3 to P5. A total of 0.5 μg of tamoxifen was injected into the stomach at P2 for mosaic deletion. For adult mice aged 7 to 8 weeks, 2 mg of tamoxifen was injected intraperitoneally for five consecutive days. For in vivo inhibition of VEGF/VEGFR2 signaling, DC101 (40 mg/kg) (BioXcel, BE0060) was injected subcutaneously into the mice at P4 and P5 and the retinas were harvested at P6. Recombinant mouse VEGF (0.5 μg in 0.5 μl) (R&D Systems, 493-MV), Dynasore (200 μM in 0.5 μl; Sigma-Aldrich), or Pitstop-2 (200 μM in 0.5 μl, Abcam) was injected into vitreous cavity using Nanoliter 2000 micro-injector (World Precision Instruments) fitted with a glass capillary pipette. All mice were anesthetized by intraperitoneal injection of a combination of anesthetics [ketamine (80 mg/kg) and xylazine (12 mg/kg)] before all the procedures and being sacrificed. Animal care and experimental procedures were performed under the approval from the Institute Animal Care and Use Committee (no. KA2018-79) of KAIST.

**Histological analyses**

Eyeballs of neonatal mice were enucleated and fixed in 4% paraformaldehyde (PFA) for 20 min at room temperature (RT). After dissecting the retinas from eyeballs, they were additionally fixed in 1% PFA for 1 hour at RT followed by several washes. Embedding of aortic rings in collagen gel was fixed in 4% PFA for 30 min at RT followed by several washes. HUVECs were fixed 2% PFA for 10 min at RT and permeabilized with PBS (0.1% Triton X-100 in PBS). Implanted LLC tumors were harvested and fixed in 4% PFA at 4°C for 6 hours, dehydrated in 30% sucrose solution for 48 hours, and embedded in tissue-freezing medium (Leica). Frozen blocks were cut into 30-μm sections. Thyroid glands were harvested and fixed in 4% PFA at 4°C for 1 hour, dehydrated in 30% sucrose solution for 20 hours, and embedded in tissue-freezing medium (Leica). Frozen blocks were cut into 20-μm sections. Small intestine was harvested and cut longitudinally to expose the lumen. After several washes with PBS, intestines were pinned on silicon plates. Samples were then postfixed at 4% PFA at 4°C for 2 hours. Samples were washed with PBS for 2 hours and with 20% sucrose and 10% glycerol in PBS overnight.

For IF staining, the fixed samples were blocked with 5% goat (or donkey) serum in PBST (0.7% Triton X-100 in PBS) for 1 hour and incubated in primary antibodies (1:200 dilution) in blocking solution at 4°C overnight. After several washes, the samples were incubated in secondary antibodies (1:1000 dilution) in blocking solution at RT for 1 hour and nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) (1:1000 dilution; Invitrogen). Then, they were

**Fig. 10. Endothelial Merlin plays a gatekeeping role in tip EC induction mediated through blocking VEGFR2 internalization at high VE-cadherin density.**

Schematic diagram depicting roles of Merlin in different density of VE-cadherin in each EC. Active Merlin forms complex with VEGFR2 and VE-cadherin at relatively high VE-cadherin density, while inactive Merlin (S518) allows high VEGFR2 internalization in ECs with low VE-cadherin density, which leads to tip EC induction.

shown highly increased filopodial protrusions in the capillaries of thyroid gland and small intestinal villi, indicating that endothelial Merlin acts as a negative switch on filopodia formation in mature ECs. This continuous action of endothelial Merlin in VEGF-enriched organs could contribute to maintaining stable blood capillary integrity.

As one of most evident phenotypic hallmarks of cancer, tumor angiogenesis is a critical pathophysiological process for meeting unregulated tumor growth (45). Tumor angiogenesis has been an attractive target for antitumor therapy, but antiangiogenic therapies have proved less effective than anticipated, mostly because they worsen severe hypoxia, the underlying cause of the proangiogenic drive in cancer (45–47). Merlin in the neuronal cells plays a gatekeeping role in physiologic angiogenesis by promoting secretions of antiangiogenic factors such as SEMA3F (semaphorin 3F) (48). Thus, similar to the case of mutation of NF2 gene in NF (19), the loss of Merlin contributes to promote tumor angiogenesis in the neuronal tissues (48). Nevertheless, because tumor angiogenesis is largely dependent on activation of VEGF-VEGFR2 signaling in the ECs (49, 50), we explored the roles of endothelial Merlin in this process using an implanted LLC tumor model in NF<sup>2<sub>AEC</sub></sup> mice. As expected, the relative vascular density and population of tip-like cells and the genes related to VEGF2 endocytosis and signaling and ERK signaling were higher in the tumor vessels of NF<sup>2<sub>AEC</sub></sup> compared with WT mice. However, the tumor growth was paradoxically delayed, mainly because of a lack of blood perfusion into the highly vascularized tumor in the NF<sup>2<sub>AEC</sub></sup> mice. Supporting these findings, tumors grown in NF<sup>2<sub>AEC</sub></sup> mice were extremely hypoxic and had more necrotic areas. These paradoxical findings are in line with the finding that blockade of DLL4 delays tumor growth by promoting nonproductive angiogenesis (51, 52). Thus, tumor EC Merlin is required for development of sufficient tumor vessels for blood supply to the growing tumor, and it presents
EdU incorporation assay for EC proliferation in the retinal vessels of neonatal mice

Six milligrams of EdU (Invitrogen, A10044) was dissolved in 1 mL of Milli-Q water as a stock solution. Then, 5 μL of the stock solution per gram of body weight was intraperitoneally injected 3 hours before the anesthesia. EdU-incorporated cells in the isolated retinas were detected with the Click-it EdU Alexa Fluor 555 Imaging Kit (Invitrogen, C10338) according to the manufacturer’s instructions.

Vascular leakage assay

For vascular leakage assay in the retina and thyroid glands, 50 μL of tetramethylrhodamine-conjugated dextran (25 mg/mL, 10 kDa; Sigma-Aldrich, D1816) and 50 μL of DyLight 488–conjugated Lycopersicon esculentum lectin (1.0 mg/mL; Vector Laboratories) were mixed and the mixture was intravenously injected into the mice. Ten minutes later, the retinas and thyroid glands were harvested and fixed in 4% PFA for 20 min. After washing with PBS, they were placed on microscope glass slides with VECTASHIELD.

Cell culture

Primary HUVECs were purchased from Lonza; cultured in EGM2 media (Lonza) at 37°C, 5% CO2, and 95% relative humidity; and used passages third to sixth for this study. HUVECs were plated at 1.25 × 10^6 per cm^2 for sparsely confluent culture and at 0.75 × 10^6 per cm^2 for densely confluent culture and incubated for 24 hours before the experiments.

RNA interference and migration assay in HUVECs

siRNA sequences were designed for human NF2 (5’-GAGGAG-CACAACCAAACAGC-3’) and GL2 (negative control; 5’-CGTACG-CGGAATATCTCGA-3’) according to previous report (53). HUVECs were transfected with the siRNA using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s protocol. The HUVECs were harvested 48 hours after transfection, and immunoblotting was performed to evaluate knockdown efficiency of Merlin. At 48 hours after siRNA transfection, the HUVECs were seeded on eight-well glass slide (Lab-Tek, 154534) and incubated until densely confluent. Then, scratch wounding was performed with a 10-μl pipette tip, and the cells were incubated with EGM-2 media for 9 hours.

Wound healing migration assay in cultured HUVECs

HUVECs were seeded at ~7 × 10^4 cells per each well of Culture-Insert 2 Well (Ibidi, #81176). After 24 hours of seeding, the insert was removed and filled with fresh EGM-2 medium. After 9 hours, images were taken and cell migration in the open wound area was quantified by ImageJ.

Ex vivo aortic ring assay

Aortic ring assay was performed as previously described (54). Aortas of the mice were harvested at the indicated days; incubated in Opti-MEM (Life Technologies) for 12 hours; cut into 1-mm-thick segments; embedded in type I collagen gel (Millipore) in a 96-well plate; incubated with Opti-MEM containing fetal bovine serum (FBS) (2%; HyClone) and VEGF (50 ng/mL; R&D Systems), Angpt2 (400 ng/mL; R&D Systems), bFGF (50 ng/mL; PeproTech), or LPA (5 μM; Sigma-Aldrich) for 2 days; and IF stained. Images for sprouting and microvessel growth were obtained using a Cell Observer (Carl Zeiss). Number of sprouts per ring was counted manually, and microvessel length from edge of aortic ring to the end of microvessel was measured using an ImageJ software [National Institutes of Health (NIH)].

RNA extraction and quantitative reverse transcription polymerase chain reaction

Total RNA was extracted from samples using RNeasy Mini Kit (QIAGEN) according to the manufacturer’s protocols. A total of 1 μg of extracted RNA was transcribed into cDNA using GoScript Reverse Transcription System (Promega). cDNA was mixed with primers and FastStart SYBR Green Master (Roche), and mRNA expression levels were measured by Real-Time PCR QuantStudio3 (Thermo Fisher Scientific). The primers were designed using Primer-BLAST and listed in table S1.

Filopodia formation assay in cultured HUVECs

HUVECs were seeded at ~7 × 10^4 cells per each well of eight-well glass slide (Lab-Tek, 154534), transfected with siRNA, and incubated with 10% FBS containing EGM-2 medium for 48 hours. After scratching the wound with the 200-μl pipette tip, the cells were incubated with...
10% FBS containing EGM-2 for 9 hours and then switched with serum-free EBM-2 and incubated for 12 hours. At 6 hours after VEGF (50 ng/ml) stimulation, filopodia formation was analyzed by IF staining.

**In vivo VEGF internalization assay**

After anesthesia of the neonates, we injected Alexa Fluor 488–labeled VEGF (0.5 µg in 0.5 µl) generated by Alexa Fluor 488 microscale protein labeling kit (A30006, Invitrogen) into vitreous cavity using Nanoliter 2000 micro-injector (World Precision Instruments) fitted with a glass capillary pipette and waited for indicated times. The retinas were harvested and IF stained as described above.

**Immunoblotting and immunoprecipitation assays**

For immunoblotting, the cells were lysed on ice in radioimmuno-precipitation assay lysis buffer supplemented with protease and phosphatase inhibitors (CST, #5872). Cell lysates were centrifuged for 10 min at 4°C and 12,000 rpm. Protein concentrations of the supernatants were quantitated using the detergent-insensitive Pierce BCA protein assay kit (Thermo Scientific, 23227). Sample loading buffer was added to total protein lysates, and samples were heated at 95°C for 5 min. Aliquots of each protein lysate (10 to 20 µg) were subjected to SDS–polyacrylamide gel electrophoresis. For immunoprecipitation analysis, cells were lysed on ice with NETN buffer [20 mM tris-hCl (pH 8.0), 100 mM NaCl, 1 mM EDTA, and 0.5% NP-40] with protease and phosphatase inhibitors (CST, #5872). Cell lysates were centrifuged, and the protein concentration of the supernatants were quantitated (Thermo Scientific, 23227) as above. Each supernatant of protein samples was incubated with anti–VEGFR2 antibody (CST, #2479) for 12 hours at 4°C. After 2-hour incubation of 35 µl of Pierce Protein A/G agarose (Thermo Scientific, 20421) at 4°C, agarose were washed in cold NETN buffer three times. In case of SBP-tagged retroviral infection, infected cell lysates were incubated with Pierce Streptavidin Agarose (Thermo Scientific, 20353) for 2 hours at 4°C without antibody incubation. Sample loading buffer was added, and the samples were denatured at 95°C for 5 min. Aliquots of each protein lysate (1 mg) were subjected to SDS–polyacrylamide gel electrophoresis. Normal rabbit IgG (CST, #2729) was used as a negative control. After electrophoresis, protein was transferred to nitrocellulose membranes and blocked for 30 min with 3% bovine serum albumin (BSA) in TBST (0.1% Tween 20 in tris-buffered saline). Primary antibodies were incubated overnight at 4°C. Primary antibodies used for immunoblotting were as follows: rabbit anti-p-VEGFR2 (Y1175) monoclonal (CST, #2478), rabbit anti-p-ERK1/2(Thr 202/Tyr 204) monoclonal (CST, #4370), mouse anti-NF2 monoclonal (Abcam, ab88957), rabbit anti–β-actin monoclonal (Sigma-Aldrich, A5441), rabbit anti–VEGFR2 monoclonal (CST, #2479), rabbit anti–VE-cadherin monoclonal (CST, #2500), rabbit anti–Tie2 monoclonal (CST, #7403), rabbit anti–VEGFR3 monoclonal (Abcam, ab27278), rabbit anti–p-NF2 (S518) polyclonal (Abcam, ab2478), mouse anti–Flag monoclonal (Sigma-Aldrich, F3165), and rabbit anti–GAPDH monoclonal (CST, #5174S). After washes, membranes were incubated with anti-rabbit (CST, #7074) or anti-mouse (CST, #7076) secondary peroxidase–coupled antibody for 1 hour at RT. Target proteins were detected using ECL Western blot solution (Millipore, WBKLS0500).

**Retroviral generation and infection**

SBP–Flag–tagged human NF2 cDNA was cloned into the pMSCVpuro vector (Clontech, K1062-1) and designated “Flag-NF2 WT.” Nonphosphorylatable NF2 (Flag-NF2-S518A) and phosphomimetic NF2 (Flag-NF2-S518D) were generated by overlap extension polymerase chain reaction (PCR) cloning. Partially overlapping mutant primers oriented in the inverse direction were used to amplify the point mutated-NF2 cDNA and were cloned into pMSCV-puro vector. To generate retroviruses in human embryonic kidney 293T cells, the indicated vectors were transfected with the vectors encoding gag/pol (Addgene) and vesicular stomatitis virus glycoprotein (Addgene) using polyethylenimine hydrochloride (Polysciences, 24885-2) for 12 hours, and then, the culture medium was changed with a fresh medium. After 48 hours of transfection, medium was harvested and centrifuged to remove dead cells. HUVECs were infected with the retrovirus using polybrene (Sigma-Aldrich, TR-1003-G). The pMSCVpuro vector was used as a control vector.

**In vitro VEGFR2 internalization assay**

HUVECs were incubated for 12 hours in EBM-2 media, treated with VEGF (50 ng/ml), and incubated at 4°C for 30 min. Then, they were transferred to 37°C for indicated times. To stop the reaction and remove plasma membrane-bound VEGF, the cells were washed for 15 min with acid solution [PBS (pH 2.7), containing 25 mM glycine and 3% BSA]. The cells were washed with PBS, fixed, and IF stained with mouse anti–VEGFR2 monoclonal antibody (Abcam, Ab9530) and rabbit anti–Rab5 (CST, #3547) monoclonal, rabbit anti–Rab7 (CST, #9367) monoclonal, or rabbit anti–Rab11 (CST, #3539) monoclonal antibody for 12 hours and secondary antibody for 1 hour to detect internalized VEGFR2.

**Subcutaneous LLC tumor model**

LLC cells were obtained from American Type Culture Collection. To generate implanted LLC tumor models, suspensions of 1 × 106 LLC cells in 100 µl were subcutaneously injected into the dorsal flank of adult C57BL/6J mice at 1 week after or 6 days before the consecutive tamoxifen treatment. Tumor volumes were measured at indicated time points, and they were calculated according to the formula 0.5 × A × B², where A is the longest diameter of a tumor and B is its perpendicular diameter. At indicated days later, the mice were anesthetized, and tumor tissues were harvested for further analyses.

**In vivo perfusion assay**

For a vascular perfusion analysis in the tumors, 100 µl of DyLight 488–conjugated L. esculentum lectin (1.0 mg/ml; Vector Laboratories) was intravenously injected via tail vein into the tumor bearing mice. At 30 min later, the mice were anesthetized and perfused with 1% PFA via intracardiac injection to remove circulating lectin, and tumors were harvested before being sacrificed. IF staining of tumor was performed as described above.

**Morphometric analyses**

Morphometric measurements of retinas, HUVECs, and tumors were performed by using the ImageJ software (NIH). Radial length of retinal vessel was measured as the distance from optic disc to the peripheral vascular front in the leaflet of retina and averaged. Number of branching points was measured manually in 200 µm–by–200 µm fields located between an artery and a vein at front in retina and averaged. Vascular density was measured as CD31+ retinal vessel area per total measured area of the retina and presented as %. A number of filopodia and sprouts were first measured in 200 µm–by–200 µm fields and then normalized to CD31+ vessel area in...
cells were stained with DAPI (Sigma-Aldrich) and CD45− tdTomato+ rat anti-CD45 (559864, BD Biosciences). To discriminate dead cells, single-cell suspensions were incubated for 30 min with APC-conjugated 1 hour. After myelin removal by 20% albumin bovine (Biosesang), Worthington), and Liberase TM (0.125 mg/ml; Roche) at 37°C for μm; g/ml; μm; μm; μm.

were harvested at P9; cut into small pieces; and digested in buffer containing collagenase type II (Worthington), Dispase (Gibco, 17105041), and deoxyribonuclease (DNase) I (Roche, 10104159001) at 37°C for 30 min. Tissues were gently agitated, strained with a 100-μm nylon mesh to remove cell clumps, incubated in ACK lysis buffer for 2 min to remove erythrocytes, and strained with a 40-μm nylon mesh. Single-cell suspensions were incubated for 20 min with anti-CD45 Microbeads (Miltenyi). After depleting CD45+ cells using AutoMACS (Miltenyi), according to the manufacturer’s instructions, anti-CD31 Microbeads (Miltenyi) were incubated for 20 min. After collecting CD31+ and CD31− cells, cells were lysed for Western blot. For brain EC isolation, brains were harvested at P9; cut into small pieces; and digested in buffer containing papain (30 U/ml; Worthington), DNase (40 μg/ml; Worthington), and Liberase TM (0.125 mg/ml; Roche) at 37°C for 1 hour. After myelin removal by 20% albumin bovine (Biosesang), single-cell suspensions were incubated for 30 min with APC-conjugated rat anti-CD45 (559864, BD Biosciences). To discriminate dead cells, cells were stained with DAPI (Sigma-Aldrich) and CD45+ ‘‘tdTomato+’’ cells were sorted with FACS Aria II (BD Biosciences).

**Isolation of mouse lung and brain ECs**

After anesthesia, lungs were harvested at P6; cut into small pieces; and digested in buffer containing collagenase type II (Worthington), Dispase (Gibco, 17105041), and deoxyribonuclease (DNase) I (Roche, 10104159001) at 37°C for 30 min. Tissues were gently agitated, strained with a 100-μm nylon mesh to remove cell clumps, incubated in ACK lysis buffer for 2 min to remove erythrocytes, and strained with a 40-μm nylon mesh. Single-cell suspensions were incubated for 20 min with anti-CD45 Microbeads (Miltenyi). After depleting CD45+ cells using AutoMACS (Miltenyi), according to the manufacturer’s instructions, anti-CD31 Microbeads (Miltenyi) were incubated for 20 min. After collecting CD31+ and CD31− cells, cells were lysed for Western blot. For brain EC isolation, brains were harvested at P9; cut into small pieces; and digested in buffer containing papain (30 U/ml; Worthington), DNase (40 μg/ml; Worthington), and Liberase TM (0.125 mg/ml; Roche) at 37°C for 1 hour. After myelin removal by 20% albumin bovine (Biosesang), single-cell suspensions were incubated for 30 min with APC-conjugated rat anti-CD45 (559864, BD Biosciences). To discriminate dead cells, cells were stained with DAPI (Sigma-Aldrich) and CD45+ ‘‘tdTomato+’’ cells were sorted with FACS Aria II (BD Biosciences).

**Bulk RNA sequencing and data analysis**

RNA from the fluorescein-activated cell sorting (FACS)−sorted cells was isolated using the RNeasy Plus Micro Kit (QIAGEN) according to the manufacturer’s instructions. RNA quality was checked using a 2100 Bioanalyzer (Agilent). RNA library construction was performed with the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (NEB) according to the manufacturer’s instructions. Libraries were validated with the Bioanalyzer and Qubit Fluorometric Quantitation (Thermo Fisher Scientific). The NextSeq 500/550 mid Output v2 Kit was used for sequencing with a NextSeq 550 (Illumina) to generate 75−base pair pair-end reads. The quality assessment of raw sequence data was performed using FastQC (version: FastQC 0.11.3; www.bioinformatics.babraham.ac.uk/projects/fastqc/). No samples were discarded from the analysis. RNA-seq data analysis was performed as described previously (55) with some modifications. Sequenced reads were aligned to the mm10 mouse genome assembly (GRCh38; the mouse genome was downloaded from the iGenomes portal) reference genome with STAR (version 2.7.3a), and the aligned reads were used to quantify mRNA expression by using HTSeq-count (version 0.6.1). Differentially expressed genes were presented using hypergeometric calculation implemented in the DESeq2 Bioconductor package in R statistical language. To identify genes with notable expression, we used scatter plotting and hierarchical clustering function in SeuratMonk (version 1.45.4, Babraham Bioinformatics SeqMonk Project; www.bioinformatics.babraham.ac.uk/projects).

Curated gene sets derived from the Kyoto Encyclopedia of Genes and Genomes pathway database and Broad Institute Molecular Signatures Database were used, and multiple lists of enriched gene sets were generated using the GSEA algorithm (56). GO analysis was performed with the g-Profiler (http://biit.cs.ut.ee/gprofiler/).

**Droplet-based scRNA-seq**

For scRNA-seq on LLC tumor ECs, FACS-sorted live ECs were collected from two mice for control group and three mice for Nj2ΔEC group. Live EC single cells were sorted to processed using 10X Chromium Single-Cell 3′ Reagent Kit v3 (10X Genomics) according to the manufacturer’s instructions. Briefly, sorted ECs were suspended in 2% BSA solution and mixed with RT reagent mix and RT primer then added to each channel of 10X chips. ECs were separated into Gel Beads in Emulsion where RNA transcripts from single cells were barcoded, and then, cDNA libraries were constructed and amplified. SPRI beads (Beckman Coulter) were used for appropriate size selection of cDNA, and products were ligated with adaptor and amplified by sample-index PCR. Double-sized size selections using SPRI beads were followed, and the final library constructions were diluted in 10-fold and ran on the Agilent Bioanalyzer High Sensitivity Chip for quality control. Single-cell library sequencing was conducted using Illumina HiSeq-X platform. The sequenced data of single-cell libraries were demultiplexed and aligned to mouse reference genome (mm10) by Cell Ranger software 3.0.0 provided by 10X Genomics. Raw expression matrices were then built by using Read10X function in Seurat (version 3.1.1). For cell-based quality control, low-quality cells detected with less than 500 and more than 8000 genes and putative dead cells with high mitochondrial gene percentage [>10% of total unique molecular identifier (UMI) counts] were discarded. For gene-based filtering, genes expressed in less than three cells were removed. After removal of unwanted cells and genes, normalization of raw expression matrices was performed by dividing UMI counts for each gene per cell by the total sum of UMI counts in a given cell, multiplied by 10,000 and log-transformed, producing log counts per million−like values. Then, gene-based scaling was performed while regressing out variables such as number of UMIs and mitochondrial gene percentage. For clustering and downstream analysis, R package Seurat was used. First, variable genes for datasets were identified by FindVariableFeatures function in Seurat with options: selection.method = “vst.” Then, principal components analysis was performed, and top 20 principal components were used for further analysis including uniform manifold approximation and projection for two-dimensional visualization, building shared nearest neighborhood graph, and Louvain algorithm for cluster identification. After initial clustering, non-ECs (e.g., CD45+ hematopoietic origin and immune cells, PDGFR+ stromal cells and ECAM1+ epithelial cells, and others) were removed from the dataset. Last, another round of clustering was performed on remaining
PECAM1+/VE-cadherin+ cells. Cluster-specific marker genes were regarded as differentially expressed genes for each cluster identified using FindMarkers function in Seurat on the RNA assay of Seurat object with following options: test.use = "MAST," min.pct = 0.25, min.diff.pct = 0.25. For GO and pathway analyses, top 100 differentially expressed genes were used as input for Enrichr (42).

Transcriptional profile analysis of microarray data
GSEA was performed with v4.0.3 of the Molecular Signature Database (www.broadinstitute.org/gsea/msigdb), and the gene sets that were <0.05 nominal P value were stated.

Statistics and reproducibility
No statistical methods were used to predetermine sample size. The experiments were randomized and investigators were blinded to allocation during experiments and outcome analyses. All values are presented as means ± SD. Statistical significance was determined by the two-tailed unpaired t test between two groups or Welch’s one-way analysis of variance (ANOVA) test followed by Dunnett’s T3 for multiple group comparison. Statistical analysis was performed using GraphPad Prism 7.0 (GraphPad software) or the R statistical environment (http://r-project.org). Statistical significance was set to P < 0.05.

SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at https://science.org/doi/10.1126/sciadv.abn2611

REFERENCES AND NOTES
1. R. Blanco, H. Gerhardt, VEGF and Notch in tip and stalk cell selection. Cold Spring Harb. Perspect. Med. 3, a006569 (2013).
2. I. Geudens, H. Gerhardt, Coordinating cell behaviour during blood vessel formation. Development 138, 4569–4583 (2011).
3. C. Margadant, Positive and negative feedback mechanisms controlling tip/stalk cell identity during sprouting angiogenesis. Angiogenesis 23, 75–77 (2020).
4. H. Gerhardt, M. Goldberg, M. Fruttiger, C. Ruhberg, A. Lundkvist, A. Abramsson, M. Jeltsch, C. Mitchell, K. Altoa, D. Shima, C. Betsholtz, VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 161, 1163–1177 (2003).
5. H. Gerhardt, VEGF and endothelial guidance in angiogenic sprouting. Organogenesis 4, 241–246 (2008).
6. M. E. Pitulescu, I. Schmitz, B. D. Giaimo, T. Antoine, F. Berkenfeld, F. Ferrante, H. Park, M. Ehling, D. Biljes, S. F. Rocha, U. H. Langen, M. Strehling, T. Nagasawa, N. Ferrara, T. Borggreve, R. H. Adams, Dll4 and Notch signalling coupling sprouts angiogenesis and artery formation. Nat. Cell Biol. 19, 915–927 (2017).
7. M. Hellstrom, L.-K. Phng, J. J. Hofmann, E. Wallgard, L. Coutals, P. Lindblom, J. Alva, A.-K. Nilsson, L. Karlsson, N. Gasano, K. Yoon, J. Rossant, M. L. Iruegas-Anto, M. Kalén, H. Gerhardt, C. Betsholtz, Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 455, 776–780 (2007).
8. M. Simons, E. Gordon, L.-C. Welsh, Mechanisms and regulation of endothelial VEGF receptor signalling. Nat. Rev. Mol. Cell Biol. 17, 611–625 (2016).
9. A. K. Olsson, A. Dimberg, J. Kreuger, L. Claesson-Welsh, VEGF receptor signalling—In control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359–371 (2006).
10. M. Nakayama, A. Nakayama, M. van Lessen, H. Yamamoto, S. Hoffmann, H. C. A. Drexler, N. Itoh, T. Hirose, G. Breier, D. Vestweber, J. A. Cooper, S. Ohno, K. Kaibuchi, R. H. Adams, Spatial regulation of VEGF receptor endocytosis in angiogenesis. Nat. Cell Biol. 15, 249–260 (2013).
11. S. P. Herbert, D. Y. R. Stainier, Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat. Rev. Mol. Cell Biol. 12, 551–564 (2011).
12. M. Simons, An inside view: VEGF receptor trafficking and signalling. Physiology (Bethesda) 27, 213–222 (2012).
13. J. Zink, M. Frye, T. Frömel, C. Carltoni, D. John, D. Schreier, A. Weigert, H. Laban, G. Salinas, H. Stingl, L. Günther, R. Popp, J. Hu, B. Vanhollebeke, H. Schmidt, A. Acker-Palmer, T. Renné, I. Fleming, P. M. Benz, EVL regulates VEGF receptor-2 internalization and signaling in developmental angiogenesis. EMBO Rep. 22, e48961 (2021).
38. F. Zhang, G. Zarkada, J. Han, J. Li, A. Dubrac, R. Ola, G. Genet, K. Boyé, P. Michon, S. E. Künel, J. P. Camporez, A. K. Singh, G. H. Fong, M. Simons, P. Tso, C. Fernández-Hernando, G. I. Shulman, W. C. Sessa, A. Eichmann, Lacteal junction zipperng protects against diet-induced obesity. Science 361, 599–603 (2018).

39. J. S. Park, I. K. Kim, S. Han, I. Park, C. Kim, J. Bae, S. J. Oh, S. Lee, J. H. Kim, D. C. Woo, Y. He, H. G. Augustin, I. Kim, D. Lee, G. Y. Koh, Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell 30, 953–967 (2016).

40. Q. Zhao, A. Eichten, A. Parveen, C. Adler, Y. Huang, W. Wang, Y. Ding, A. Adler, T. Nevins, M. Ni, Y. Wei, G. Thurston, Single-cell transcriptomes reveals endothelial cell heterogeneity in tumors and changes following antiangiogenic treatment. Cancer Res. 78, 2370–2382 (2018).

41. S. H. Jeong, M. J. Yang, S. Choi, J. M. Kim, G. Y. Koh, Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour. Nat. Commun. 12, 4405 (2021).

42. M. V. Kuleshov, M. R. Jones, A. D. Rouillard, N. F. Fernandez, Q. Duan, Z. Wang, S. Koplev, Effect of merlin phosphorylation on YAP inhibition. EMBO Rep. 17, 64–78 (2016).

43. E. I. Surace, C. A. Haipek, D. H. Gutmann, Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene 23, 580–587 (2004).

44. M. G. Lampugnani, A. Zanetti, M. Corada, T. Takahashi, G. Balconi, F. Breviario, F. Orsenigo, A. Cattelino, R. Kemler, T. O. Daniel, E. Dejana, Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J. Cell Biol. 161, 793–804 (2003).

45. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011).

46. O. Casanova, D. J. Hicklin, G. Bergers, D. Hanahan, Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299–309 (2005).

47. J. M. L. Ebo, R. S. Kerbel, Antiangiogenic therapy: Impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210–221 (2011).

48. H. K. Wong, A. Shimizu, N. D. Kirkpatrick, I. Garkavtsev, A. W. Chan, E. di Tomaso, M. Klagsbrun, R. K. Jain, Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism. Neoplasia 14, 84–94 (2012).

49. L. M. Ellis, D. J. Hicklin, VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat. Rev. Cancer 8, 579–591 (2008).

50. Z. Zhang, K. G. Neiva, M. W. Lengs, I. M. Ellis, J. E. Nör, VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 17, 499–512 (2010).

51. I. Noguera-Troise, C. Daly, N. J. Papadopoulos, S. Coetzee, P. Boland, N. W. Gale, H. Chen Lin, G. D. Yancopoulos, G. Thurston, Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444, 1032–1037 (2006).

52. G. Thurston, I. Noguera-Troise, G. D. Yancopoulos, The Delta paradox: DLL4 blockage leads to more tumour vessels but less tumour growth. Nat. Rev. Cancer 7, 327–331 (2007).

53. M. Kim, M. Kim, S. J. Park, C. Lee, D. S. Lim, Role of angiomotin-like 2 mono-ubiquitination on Yap inhibition. EMBO Rep. 17, 64–78 (2016).

54. M. Baker, S. D. Robinson, T. Lechertier, P. R. Barber, B. Tavora, G. D’Amico, D. T. Jones, B. Vojnovic, K. Hodivala-Dilke, Use of the mouse aortic ring assay to study angiogenesis. Nat. Protoc. 7, 89–104 (2011).

55. H. W. Jeong, B. H. Rodríguez, J. M. Kim, K. P. Kim, R. Enríquez-Gasca, J. Yoon, S. Adams, H. R. Scholer, J. M. Vaquerizas, R. H. Adams, Transcriptional regulation of endothelial cell behavior during sprouting angiogenesis. Nat. Commun. 8, 726 (2017).

56. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545–15550 (2005).

Acknowledgments: We thank S. Seo (IBS) for technical assistance. We also thank Y. Kubota (Keio University, Tokyo, Japan) for VE-cadherin Cre-ER\(^{2}\) mice and D.-S. Lim (KAIST, Daejeon, Korea) for Yap\(^{lox/lox}\) and Taz\(^{lox/lox}\) mice. Funding: This study was supported by the Institute for Basic Science (IBS-R025-D1-2015 to G.Y.K.) funded by the Ministry of Science, ICT and Future Planning, Korea. Author contributions: J.H.B. designed, organized, and performed all experiments, generated the figures, and wrote the paper. M.Y.J. performed scRNA-seq and analyzed the datasets. J.K. performed bulk RNA-seq and analyzed the datasets. S.P.H. and J.-H. provided technical supports. J.W.K. provided bulk RNA-seq data and discussed the findings. Y.H.K. and G.Y.K. designed, organized, supervised the project, and wrote the paper.

Competing interests: The authors declare that they have no financial or other competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Bulk RNA sequencing data and single-cell RNA sequencing data are available in National Center for Biotechnology Information’s Gene Expression Omnibus under accession number GSE186189 (bulk RNA-seq on brain ECs from P9 pups) and GSE186162 (scRNA-seq on tumor ECs from implanted LLC tumor).

Submitted 15 November 2021
Accepted 28 April 2022
Published 10 June 2022
10.1126/sciadv.abn2611